Search the Newsreel

Ligand (LGND) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Melanie HermanChief Executive Officer - Todd DavisChief Financial Officer - Octavio EspinozaVice President of Portfolio Strategy and Investments - Lauren Hay TAKEAWAYS Total …

Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock

On the IBD 50 and the latest list of new buys by top funds, Ligand stock targets a breakout but faces this test first. Continue Reading

Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow While Earnings Look Overvalued

LGND: XOMA Acquisition Closed

By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH NOTE Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported second quarter 2026 results boasting total revenue and income of $63.7 million, a 34% year over year increase. Adjusted core earnings per share (EPS) of $2.37 …

Should Ligand Pharmaceuticals’ (LGND) Strong Q2 Profit Rebound and Reaffirmed 2026 Guidance Require Action From Investors?

Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results

California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND

Ligand Pharmaceuticals (LGND) Stock Pulls Back As Royalty Profit Strength Meets Valuation Doubts

Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps

Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508

Ligand Pharmaceuticals (LGND) Posts Strong Q2 Results, Is The Upside Already Priced In?

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...

This article first appeared on GuruFocus. Total Revenue: $64 million, up 34% year over year. Royalty Revenue: $48 million, up 32% year over year, driven by strength from Filspari, Otuber, and Zilsubme. Adjusted Diluted EPS: $2.37, up 48% year over year. GAAP Diluted EPS: …

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its …

Ligand Pharmaceuticals (NASDAQ:LGND) Issues FY 2026 Earnings Guidance

Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Ligand stock slipped early Thursday after the royalty powerhouse reported better-than-expected earnings and sales. Continue Reading

Ligand Reports Second Quarter 2026 Financial Results

Ligand Pharmaceuticals Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals …

Ligand Adds More Than 120 Royalty Assets in XOMA Acquisition

Ligand Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LGND) 2026-08-06

Ligand Pharmaceuticals reported strong Q2 2026 results, driven by increased royalty revenue and adjusted earnings, and highlighted the strategic acquisition of XOMA Royalty. The company raised its full-year adjusted EPS guidance and outlined significant deployable capital for future business development. Ligand also detailed its …

Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Trimmed by Edgestream Partners L.P.

Sei Investments Co. Increases Stock Position in Ligand Pharmaceuticals Incorporated $LGND

Janus Henderson Group PLC Raises Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

Janus Henderson Group PLC increased its stake in Ligand Pharmaceuticals Incorporated by 1.5% in the first quarter, now owning over 1 million shares valued at approximately $201.6 million. Institutional investors hold a significant portion of the company's stock, and Wall Street analysts maintain a …

LGND|Ligand Pharmaceuticals Inc|Price:289.855|Chg%:+2.315

Ligand Pharmaceuticals Inc. is a biopharmaceutical company that focuses on enabling scientific advancement through financing and licensing its proprietary technologies, such as Captisol and NITRICIL, to support the clinical development of medicines. The company has a market capitalization of $6.26 billion and a P/E …

Ligand Pharmaceuticals (LGND) Expected to Announce Earnings on Thursday

Castleark Management LLC Decreases Stake in Ligand Pharmaceuticals Incorporated $LGND

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Ligand Pharmaceuticals JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time …

Ligand Sets Aug. 6 Webcast for Second-Quarter Results

Bessemer Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated $LGND

Bessemer Group Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 358.8% in Q1, now owning 107,859 shares worth $21.5 million. Despite missing recent earnings and revenue estimates, Wall Street maintains a "Moderate Buy" consensus rating with an average price target of $304.00, …

ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Ligand Pharmaceuticals Incorporated (LGDN). It provides a detailed table including each ETF's market value, weight of LGDN in the fund, issuer, management style, focus (e.g., small cap, health care), expense ratio, assets …

Future Fund LLC Grows Stock Position in Ligand Pharmaceuticals Incorporated $LGND